SYK

SYK

USD

Stryker Corporation Common Stock

$356.030+1.400 (0.395%)

실시간 가격

Healthcare
의료 기기
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$354.630

고가

$357.500

저가

$352.500

거래량

1.68M

기업 기본 정보

시가총액

136.2B

산업

의료 기기

국가

United States

거래 통계

평균 거래량

1.39M

거래소

NYQ

통화

USD

52주 범위

저가 $329.16현재가 $356.030고가 $406.19

AI 분석 리포트

마지막 업데이트: 2025년 11월 2일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

After a Steep Plunge, Is Stryker (SYK) Poised for a Comeback?

Generated: November 02, 2025, 11:15 AM EDT

Wall Street's Verdict: Analysts Stand Firm Despite the Turmoil

Even as Stryker's stock price took a beating, the mood among market analysts remains surprisingly upbeat. The latest reports show a strong consensus. Barclays, for instance, recently boosted its price target to an ambitious $453, maintaining an "Overweight" rating. BTIG followed suit, nudging its target up to $410 with a solid "Buy."

There was one minor note of caution. Evercore ISI trimmed its target slightly, from $410 to $405. However, they kept their "Outperform" rating, signaling continued confidence in the company's direction. This pattern of unwavering support from analysts, even in the face of a sharp sell-off, suggests they believe the recent drop is a temporary setback, not a fundamental flaw in the business. News of the company showcasing its new trauma portfolio also adds a positive, forward-looking element to the narrative.

The Anatomy of a Sell-Off: Charting Stryker's Rocky Quarter

The last three months have been a wild ride for Stryker shareholders. The stock climbed steadily through August, peaking above $394 in early September. Then, the momentum shifted. A slow, grinding decline began, pulling the price down through the rest of the month.

Things took a dramatic turn on the final day of October. The stock plunged sharply, closing at $356.24. This wasn't a quiet drift downward; it was a stampede for the exits. Trading volume exploded to more than double its daily average, indicating a major event or a wave of panic selling. This kind of move often washes out weak hands, but it also leaves investors wondering what comes next. The stock went from a high near $395 to a low near $355 in just two months--a significant reversal that has reset the board.

The Digital Crystal Ball: AI Signals a Strong Bounce-Back

While the recent price chart looks grim, predictive algorithms are telling a completely different story. The AI forecast points to a swift and powerful rebound in the immediate future.

AI Price Forecast (Next 3 Days)

DayPredicted Change
1+1.27%
2+2.90%
3+4.29%

This forecast is backed by high confidence from the model. It seems to view the recent plunge as a classic overreaction, creating a strong buying opportunity. This optimism is fueled by the positive news sentiment and strong analyst ratings. However, the picture isn't entirely rosy. The system also flags some conflicting technical signals, like a bearish MACD crossover, and points out the company's high debt-to-equity ratio. It's a classic battle: the bearish reality of the recent price drop versus the bullish promise of a data-driven forecast.

The Bottom Line

The data for Stryker Corporation presents a fascinating contradiction. On one hand, you have a brutal, high-volume sell-off that has shaken investor confidence. On the other, you have firm conviction from Wall Street analysts and a highly confident AI model predicting a significant short-term recovery.

For a medium-term investor who can stomach some volatility, the current situation could present an opportunity. The AI model suggests the selling is overdone. A strategy based on this data would involve entering a position near the recent lows, anticipating a bounce toward the AI's target of $376.39.

A cautious approach is warranted. The provided data suggests potential entry points between $371.16 and $373.38. To manage risk, a stop-loss at $332.11 would be prudent to protect against a continued slide. If the AI's predicted bounce materializes, taking profits around the $376.39 level would align with the model's short-term outlook. The conflicting technical and fundamental signals--especially the high debt--should not be ignored and add a layer of risk to this potential trade.


Disclaimer: This report is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation of an offer to buy any security. The analysis is based solely on the structured data provided and may not reflect all market conditions or future events. Investing in stocks involves risk, including the possible loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

관련 뉴스

Analyst Upgrades

Truist Securities Reiterates Hold on Stryker, Lowers Price Target to $392

Truist Securities analyst Richard Newitter reiterates Stryker with a Hold and lowers the price target from $407 to $392.

더 보기
Truist Securities Reiterates Hold on Stryker, Lowers Price Target to $392
Analyst Upgrades

Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $405

Evercore ISI Group analyst Vijay Kumar maintains Stryker with a Outperform and lowers the price target from $410 to $405.

더 보기
Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $405
Analyst Upgrades

BTIG Maintains Buy on Stryker, Raises Price Target to $410

BTIG analyst Ryan Zimmerman maintains Stryker with a Buy and raises the price target from $408 to $410.

더 보기
BTIG Maintains Buy on Stryker, Raises Price Target to $410
Analyst Upgrades

Barclays Maintains Overweight on Stryker, Raises Price Target to $453

Barclays analyst Matt Miksic maintains Stryker with a Overweight and raises the price target from $443 to $453.

더 보기
Barclays Maintains Overweight on Stryker, Raises Price Target to $453
BusinessWire

Stryker to Feature Expanding Trauma Portfolio at the Orthopaedic Trauma Association Annual Meeting 2025

Stryker (NYSE:SYK), a global leader in medical technologies, will showcase new additions to its trauma offerings at the Orthopaedic Trauma Association (OTA) Annual Meeting, October 15–18, in Phoenix, Ariz. (booth #601).

더 보기
Stryker to Feature Expanding Trauma Portfolio at the Orthopaedic Trauma Association Annual Meeting 2025

AI 예측Beta

AI 추천

강세

업데이트 시간: 2025년 11월 10일 오전 08:51

약세중립강세

70.0% 신뢰도

리스크 & 트레이딩

리스크 수준3/5
중위험
적합 대상
보수적
트레이딩 가이드

진입점

$356.64

익절

$374.33

손절

$320.40

핵심 요소

PDI 6.6이(가) ADX 11.0과 함께 MDI 5.9 위에 있어 강세 추세를 시사합니다.
현재 가격이 지지선($355.67)에 매우 근접하여 강력한 매수 기회를 시사합니다.
거래량은 평균(14,928)의 10.5배로 극도로 강력한 매수 압력을 나타냅니다.
MACD -0.1054이(가) 신호선 -0.0445 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기